论文部分内容阅读
目的 :制备阿苯达唑聚氰基丙烯酸酯口服纳米球 (ABZ-PBCA-NP) ,并考察其体外累积溶出速率。方法 :采用乳化聚合二步法制备阿苯达唑口服纳米球 ,以包封率为考察指标 ,应用 L9(3 4 )正交试验设计优化处方。同时 ,以原料药混悬液对照 ,进行体外动态释药试验。结果 :当空白纳米球 p H为 5 .0 ,与阿苯达唑液的体积比 1.2∶ 1,氰基丙烯酸正丁酯浓度为 1%时 ,制备口服纳米球的包封率最高 ,即 (60 .0 3± 5 .5 0 ) %。在 p H=5 .0的磷酸缓冲溶液中 ,阿苯达唑口服纳米球释药符合 Higuchi方程 ,阿苯达唑混悬液释药符合威布尔分布函数。结论 :二步优化法制备阿苯达唑口服纳米球具有较高的包封率和明显的缓释作用
OBJECTIVE: To prepare albendazole polycyanoacrylate oral nanospheres (ABZ-PBCA-NP) and to investigate its cumulative dissolution rate in vitro. METHODS: Albendazole orally administered nanospheres were prepared by the two-step emulsification polymerization. The entrapment efficiency was taken as the index of study. The orthogonal design of L9 (34) was used to optimize the formulation. At the same time, the API suspension was used for dynamic in vitro drug release test. Results: When the blank nanosphere p H was 5.0 and the volume ratio of albendazole solution was 1.2:1, the concentration of n-butyl cyanoacrylate was 1%, the entrapment efficiency of oral nanospheres was the highest 60 .0 3 ± 5 .5 0)%. In p H = 5.0 phosphate buffer solution, albendazole oral nanosphere release in line with Higuchi equation, albendazole suspension release in line with the Weibull distribution function. Conclusion: The two-step optimization of albendazole oral nanospheres has a higher entrapment efficiency and significantly delayed release